Xiaoyan Li, Shengbing Zang, Yu Zhang, Lin Zheng, Chengjie Lin, Jingfeng Liu, Aimin Huang
Department of Pathology and Institute of Oncology, Fujian Medical University, Fuzhou 350004, PR China.
Liver Center, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, PR China.
Pathol Res Pract. 2014 Aug;210(8):477-81. doi: 10.1016/j.prp.2014.03.013. Epub 2014 Apr 18.
To explore the expression and role of activating transcription factor 3 in human hepatocellular carcinoma.
Immunohistochemistry, Western blot assay and Real-time PCR were used to evaluate activating transcription factor 3 protein and gene level in HCC clinical samples.
Activating transcription factor 3 expression is lowest in HCC, and the protein level is lower in patients with capsule invasion, while there is no association with other main clinical pathological features.
Low expression of ATF3 may function as a tumor suppressor during human hepatocellular oncogenesis and targeting ATF3 pathway might be beneficial for anti-HCC therapy.
探讨激活转录因子3在人肝细胞癌中的表达及作用。
采用免疫组织化学、蛋白质印迹分析及实时定量聚合酶链反应检测肝癌临床样本中激活转录因子3的蛋白和基因水平。
激活转录因子3在肝癌中的表达最低，包膜侵犯患者的蛋白水平较低，而与其他主要临床病理特征无关。
激活转录因子3低表达可能在人肝细胞癌发生过程中发挥肿瘤抑制作用，靶向激活转录因子3通路可能有利于肝癌治疗。
